Rabbit model in the pre-clinical studies of a new generation of coronary stents

• Autorzy: Janiszewski A. , Paslawska U. , Bialy D. , Wawrzynska M. , Noszczyk-Nowak A. , Paslawski R. , Nicpon J.
• Języki publikacji: EN

Abstrakty

EN

Coronary artery occlusion is a very important problem in human medicine. A great progress in the treatment was the introduction of stents. The most popular are drug-eluting stents, which prevent restnosis. Nowadays, more than 30 different types of stents are implanted into the coronary arteries, and these stents are still being improved. Animal models make it possible to verify theoretical assumptions and are considered very useful for understanding the mechanisms of the system response and for evaluating the effectiveness and safety of this factor. To bring the rabbit model closer to conditions under which stents are implanted, rabbits are fed a fat-rich diet, often with 0.5-2.0% cholesterol, and, occasionally, their vessel walls are damaged with a balloon, ligation narrowing the lumen, or a stent of a slightly excessive diameter, which damages the endothelium. A standard protocol for this type of experiments has not yet been developed. The rabbit model has become a very valuable and widely recognized model in pre-clinical studies of vascular stents, since it is useful for a reliable preliminary evaluation of new materials. The reactions of the human body to the new material are comparable to the reactions obtained previously in the rabbit model. Although there is no animal model perfectly imitating the conditions in human coronary arteries affected by chronic coronary disease, pre-clinical studies carried out on the rabbit model have opened new horizons for saving human health and lives.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2013
• Tom: 69
• Numer: 06
• Opis fizyczny: p.323-327,fig.,ref.

Twórcy

autor

Janiszewski A.

• Regional Specialist Hospital, Research and Development Centre Wroclaw, Kamienskiego 73a, 51-124 Wroclaw, Poland
• Department of Internal Diseases with Clinic for Horses, Dogs, and Cats, Faculty of Veterinary Medicine, University of Environmental and Life Sciences, pl.Grunwaldzki 47, 50-366 Wroclaw, Poland

autor

Paslawska U.

• Regional Specialist Hospital, Research and Development Centre Wroclaw, Kamienskiego 73a, 51-124 Wroclaw, Poland
• Department of Internal Diseases with Clinic for Horses, Dogs, and Cats, Faculty of Veterinary Medicine, University of Environmental and Life Sciences, pl.Grunwaldzki 47, 50-366 Wroclaw, Poland

autor

Bialy D.

• Department and Clinic of Cardiology, Wroclaw Medical University, Wybrzeze L.Pasteura 4, 50-367 Wroclaw, Poland

autor

Wawrzynska M.

• Department and Clinic of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland

autor

Noszczyk-Nowak A.

• Regional Specialist Hospital, Research and Development Centre Wroclaw, Kamienskiego 73a, 51-124 Wroclaw, Poland
• Department of Internal Diseases with Clinic for Horses, Dogs, and Cats, Faculty of Veterinary Medicine, University of Environmental and Life Sciences, pl.Grunwaldzki 47, 50-366 Wroclaw, Poland

autor

Paslawski R.

• Regional Specialist Hospital, Research and Development Centre Wroclaw, Kamienskiego 73a, 51-124 Wroclaw, Poland
• Department and Clinic of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland

autor

Nicpon J.

• Regional Specialist Hospital, Research and Development Centre Wroclaw, Kamienskiego 73a, 51-124 Wroclaw, Poland
• Department of Internal Diseases with Clinic for Horses, Dogs, and Cats, Faculty of Veterinary Medicine, University of Environmental and Life Sciences, pl.Grunwaldzki 47, 50-366 Wroclaw, Poland

Bibliografia

• 1. Akin I., Kische S., Rehders T. C., Schneider H., Turan G. R., Kleinfeldt T., Ortak J., Ince H., Nienaber C. A.: Very late coronary aneurysm formation with subsequent stent thrombosis secondary to drug-eluting stent. Chin. Med. J. 2011, 20, 3427-3429.
• 2. Bavry A. A., Kumbhani D. J., Helton T. J., Borek P. P., Mood G. R., Bhatt D. L.: Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am. J. Med. 2006, 12, 1056-1061.
• 3. Brasselet C., Durand E., Addad F. F., Al Haj Zen A., Smeets M. B., Laurent-Maquin D., Bouthors S., Bellon G., Kleijn D., Godeau G., Garnotel R., Gogly B., Lafont A.: Collagen and elastin cross-linking: a mechanism of constrictive remodeling after arterial injury. Am. J. Physiol. 2005, 289, H2228-2233.
• 4. Bueno R. R., Tanguay J. F., Brito F. S. Jr., Guerios E. E., Tarastchuk J. E., Sanches P. A., Andrade P. M., Rossi P. F., Bueno F. L.: Evaluation of the efficacy and safety of a stent covered with biosynthetic cellulose in a rabbit iliac artery model. J. Invasive Cardiol. 2009, 21, 392-396.
• 5. Chen M. C., Liu C. T., Tsai H. W., Lai W. Y., Chang Y., Sung H. W.: Mechanical properties, drug eluting characteristics and in vivo performance of a genipin-crosslinked chitosan polymeric stent. Biomaterials 2009, 30, 5560-5571.
• 6. Chen M., Wang X. G., Zheng B., Peng H. Y., Zhang X. Y., Zhang B., Huo Y.: Investigation of long-term implantation of BuMA stent in a porcine coronary model. Chin. Med. J. (Engl). 2012, 22, 4083-4087.
• 7. Constantinides P., Chakravarti R. N.: Rabbit arterial thrombosis production by systemic procedures. Arch. Pathol. 1961, 72, 197-208.
• 8. Doerfler A., Becker W. P., Wanke I., Goericke S. L., Mueller K. M., Blechschmid N., Flesser A., Monstadt H., Forsting M.: A novel flexible, retrievable endovascular stent system for small-vessel anatomy: preliminary in vivo data. Am. J. Neuroradiol. 2005, 26, 862-868.
• 9. Erbel R., Di Mario C., Bartunek J., Bonnier J., de Bruyne B., Eberli F. R., Erne P., Haude M., Heublein B., Horrigan M., Ilsley C., Böse D., Koolen J., Lüscher T. F., Weissman N., Waksman R.: PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007, 369, 1869-1875.
• 10. Fang S.-M., Zhang Q.-H., Jiang Z.-X.: Developing a novel rabbit model of atherosclerotic plaque rupture and thrombosis by cold-induced endothelial injury. J. Biomed. Sci. 2009, 4, 16-39.
• 11. Feoli A. M., Roehrig C., Rotta I. N., Kruger A. H., Souza K. B., Kessler A. A. M., Renz S. V., Brusque A. M., Souza D. O., Perry M. I.: Serum and liver lipids in rats and chicks fed with diets containing different oils. Nutrition 2003, 19, 789-793.
• 12. Finking G., Hanke H.: Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for athrosclerosis research. Atherosclerosis 1997, 135, 1-7.
• 13. Gershlick A. H., Baron J.: Dealing with in-stent restenosis. Heart 1998, 79, 319-323.
• 14. Gil R. J., Vassiliev D., Michalek A., Kern A., Formuszewicz R., Dobrzycki S., Lesiak M., Wójcik J., Kardaszewicz P., Lekston A.: First-in-man study of praclitaxel-eluting stent BiOSS (Bifercation Optimisation Stent System) dedicated for coronary bifurcation stenosis: three months results. Kardiol. Pol. 2012, 70, 45-52.
• 15. Hagiwara H., Hiraishi Y., Terao H., Hirai T., Sakaoka A., Sasaki M., Murota S., Inoue K., Kimura J.: Vascular responses to a biodegradable polymer (polylactic acid) based Biolimus A9-eluting stent in porcine models. EuroIntervention 2012, 6, 743-751.
• 16. Hayashi T., Esaki T., Sumi D., Mukherjee T., Inguchi A., Chaudhuri G.: Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an artheroprotective mechanism. Proc. Natl Acad. Sci. USA 2006, 103, 10485-10490.
• 17. Hehrlein C., Kovacs A., Wolf G. K., Yue N., Nath R.: A novel balloon angioplasty catheter impregnated with beta-particle emitting radioisotopes for vascular brachytherapy to prevent restenosis. First in vivo results. Eur. Heart J. 2000, 21, 2056-2062.
• 18. Joner M., Farb A., Cheng Q., Finn V. A., Acampado E., Burke A. P., Skorija K., Creighton W., Kolodgie F., Gold H. K., Virmani R.: Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-â and MCP-1. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 182-189.
• 19. Joner M., Finn A. V., Farb A., Mont E. K., Kolodgie F. D., Ladich E., Kutys R., Skorija K., Gold H. K., Virmani R.: Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006, 48, 193-202.
• 20. Karagkiozaki V. C., Logothetidis S. D., Kassavetis S. N., Giannoglou G. D.: Nanomedicine for the reduction of the thrombogenicity of stent coatings. Int. J. Nanomedicine 2010, 5, 239-248.
• 21. Kolandaivelu K., Swaminathan R., Gibson W. J., Kolachalama V. B., Nguyen-Ehrenreich K.-L., Giddings V. L., Coleman L., Wong G. K., Edelman E. R.: Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings: clinical perspective. Circulation 2011, 123, 1400-1409.
• 22. Kritchevsky D., Tepper S. A., Wright S., Czarnecki S. K., Wilson T. A., Nicolosi R. J.: Cholesterol vehicle in experimental atherosclerosis 24: avocado oil. J. Am. Coll. Nutr. 2003, 22, 52-55.
• 23. Lesiak M., Witkowski A., Maciejewski P.: Kardiologia interwencyjna - jak leczyliśmy chorych w 2010 roku? Raport Zarządu Asocjacji Interwencji Sercowo-Naczyniowych Polskiego Towarzystwa Kardiologicznego. Post. Kardiol. Interw. 2011, 7, 129-134.
• 24. Levy Y., Mandler D., Weinberger J., Domb A. J.: Evaluation of drug-eluting stents' coating durability: clinical and regulatory implications. J. Biomed. Mater. Res. B Appl. Biomater. 2009, 1, 441-451.
• 25. Lousinian S., Logothetidis S., Laskarakis A., Gioti M.: Haemocompatibility of amorphous hydrogenated carbon thin films, optical properties and adsorption mechanisms of blood plasma proteins. Biomol. Eng. 2007, 1, 107-112.
• 26. Nakazawa G., Finn A. V., John M. C., Kolodgie F. D., Virmani R.: The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am. J. Cardiol. 2007, 22, 36M-44M.
• 27. Nilsen D. W., Melberg T., Larsen A. I., Barvik S., Bonarjee V.: Late complications following the deployment of drug-eluting stents. Int. J. Cardiol. 2006, 109, 398-401.
• 28. Peuster M.: A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal - results 6-18 months after implantation into New Zealand white rabbits. Heart 2001,86, 563-569.
• 29. Phinikaridou A., Hallock K. J., Qiao Y., Hamilton J. A.: A robust rabbit model of human atherosclerosis nd atherothrombois. J. Lipid. Res. 2009, 50, 787-797.
• 30. Rekhter M. D., Hicks G. W., Brammer D. W., Work C. W., Kim J.-S., Gordon D., Keiser J. A., Ryan M. J.: Animal model that mimics atherosclerotic plaque rupture. Circ. Res. 1998, 83, 705-713.
• 31. Sabitha P. P., Vasudevan D. M., Kamath P.: Effect of high fat diet without cholesterol supplementation on oxidative stress and lipid peroxidation in New Zealand white rabbits. J. Atheroscler. Tromb. 2010, 17, 213-218.
• 32. Schwartz R. S.: Preclinical Evaluation of Drug-Eluting Stents for Peripheral Applications: Recommendations From an Expert Consensus Group. Circulation 2004, 110, 2498-2505.
• 33. Sharif F., Hynes S. O., Cooney R., Howard L., McMahon J., Daly K., Crowley J., Barry F., O'Brien T.: Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol. Ther. 2008, 16, 1674-1680.
• 34. Shimizu T., Nakai K., Morimoto Y., Ishihara M., Oishi H., Kikuchi M.: Simple rabbit model of vulnerable atherosclerotic plaque. Neurol. Med. Chir. Tokyo 2009, 40, 537-332.
• 35. Silber S., Albertsson P., Aviles F. F., Camici P. G., Colombo A., Hamm C., Jorgensen E., Marco J., Nordrehaug J. E., Rużyłło W., Urban P., Stone G. W., Wijns W.: Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC. Kardiol. Pol. 2005, 3, 265-320.
• 36. Trauwein E. A., Kunath-Rau A., Dietrich J., Drusch S., Erberdobleer H. F.: Effect of dietary fats rich in lauric, myristic, palmitic, oleic or linoleic acid on plasma, hepatic and biliary lipids in cholesterol fed rabbits. Br. J. Nutr. 1997, 77, 605-620.
• 37. Waterhouse A., Wise S. G., Yin Y., Wu B., James B., Zreigat H., McKenzie D. R., Bao S., Weiss A. S., Nq M. K., Bilek M. M.: In vivo biocompatibility of plasma-activated, coronary stent coating. Biomaterials 2012, 33, 7984-7992.
• 38. Wissler R. W., Vesselinovitch D.: Differences between human and animal atherosclerosis,. [in:] Schettler G. I., Weizel A.: Atherosclerosis, Vol. 3. Springer, New York 1974, pp. 319-325.
• 39. Yang W., Ge J., Liu H., Zhao K., Liu X., Qu X., Li W., Huang Y., Sun A., Zou Y.: Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model. Cardiovasc. Res. 2006, 72, 483-493.

Uwagi

Rekord w opracowaniu